Search

Find exactly what you’re looking for.
Search

Service
Showing 101-109 of 109 results

Steve Bannon showed ‘monumental arrogance’: Former prosecutor ABC News’ Phil Lipof spoke with Jeffrey Robbins, former chief counsel for the minority of the U.S. Senate Permanent Subcommittee on Investigations, about Steve Bannon being found guilty of contempt. January 6 Investigation: Robbins...

Jan. 6 committee to hold Thursday prime-time hearing The Jan. 6 committee said Thursday’s hearing will focus on the 187 minutes between former President Donald Trump’s speech at his rally and public statement trying to quell the riot. January 6 Investigation: Robbins Appears on ABC News to Discuss...

TAX TREATY PRIMER—AN OVERVIEW OF TAX TREATIES AND TAX TREATY PLANNING TECHNIQUES David Shapiro, Chair of the Firm's Tax Practice, will be speaking at the NYU School of Professional Studies on Monday, July 11, 2022. His topic will be "Tax Treaty Primer - An Overview of Tax Treaties and Tax Treaty...

$269 Million Construction Loan for South Florida Mixed-Use Project Is Among Largest of Its Kind “This transaction underlines the strength of Peter [Baytarian]’s vision and the importance of the Nautilus 220 project to the area,” said Anthony Kang, a partner with Saul Ewing.

ABC News Live: Jan. 6 committee focuses on efforts to pressure states Plus, the latest on the investigation into the school shooting in Uvalde, Texas. January 6 Investigation: Robbins Appears on ABC News Live to Discuss the Committee's Focus on Trump's Efforts to Pressure State Elections.

“Penny wise but pound foolish” first appeared in writing over 500 years ago. This idiom captures the wisdom of human experience in just five words: shortcuts that appear to save money are more expensive in the long run. Sometimes much more. Further proof of this eternal truth - and one taxpayer’s...

Washington, D.C., November 24, 2021 – Saul Ewing LLP served as counsel to Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) in the successful completion today of its previously announced $450 million acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The acquisition strengthens Supernus'...

For More Information
Contact us